Oncology

< Back

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

120
total
757.123
impact factor
6.309
average impact factor

Director: Gil Moreno, Antonio

group-team team group-zoom zoom group-download download

Research Areas

The Biomedical Research Group in Gynaecology promotes a high crosstalk between clinicians and researchers to cover the unmet clinical issues of gynaecological diseases. The most prominent research lines are the clinical research group, led by Dr. Antonio Gil; the ovarian cancer group, cell cycle and aneuploidy group led by Dr. Anna Santamaria; the endometrial cancer translational research group, led by Dr. Eva Colás, and the endometriosis group, led by Dr. Xavier Santamaria and Dr. Antonio Gil.

In 2017, we highlight our achievements in the CEMARK project, a molecular tool to diagnose endometrial cancer. We published Martinez-Garcia et al. Clinical Cancer Research; applied for the PCT international patent and filed a second european patent; and obtained a DTS project to fund the prototype development of the molecular tool. We participated in the IDEA2 Global program (M+Envision & MIT) and the MAP-EADA program (EADA & ACCIO) to foster the valorization of our project. Importantly, our project was awarded in both programs and the PhD student who developed the project obtained the Pioner award for innovative PhD theses (CERCA). Moreover, we unveiled the role of ALCAM in the process of myometrial infiltration and decipher the role of the RNA editing pathway in the endometrial carcinogenesis (Devis et al. Oncotarget & Altadill et al. Sci Rep). In ovarian cancer, we are leading a clinically study to ensure the security and efficacy of the M-Trap, a device intended to control the dissemination pattern of ovarian cancer and highlight our results on the tumor suppressive role of a miRNA in ovarian cancer (submitted to Clinical Cancer Research). We moved forward also in our transversal work in prostate cancer research in collaboration with the Urology group (obtaining funding from the Carlos III and the AECC-Junta de Barcelona for this). Our group obtained the SGR grant (AGAUR) to support our research.

VHIR Annual Report 2017

© FIR-HUVH Fundació Institut de Recerca Hospital Universitari Vall d’Hebron 2017 | Developed by: ondeuev